The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

The mesenchymal–epithelial transition factor (MET) proto-oncogene encodes the MET receptor tyrosine kinase. MET aberrations drive tumorigenesis in several cancer types through a variety of molecular mechanisms, including MET mutations, gene amplification, rearrangement, and overexpression. Therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Albers, Joachim, Friese-Hamim, Manja, Clark, Anderson, Schadt, Oliver, Walter-Bausch, Gina, Stroh, Christopher, Johne, Andreas, Karachaliou, Niki, Blaukat, Andree
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320478/
https://www.ncbi.nlm.nih.gov/pubmed/36999986
http://dx.doi.org/10.1158/1535-7163.MCT-22-0537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320478/
https://www.ncbi.nlm.nih.gov/pubmed/36999986
http://dx.doi.org/10.1158/1535-7163.MCT-22-0537

Ejemplares similares